Medical Advocates
Ethics and Infectious Diseases
  Ethical Challenges
Screening/Testing
 Refusal of Care/Services
Detention
Patient Exploitation
Compulsory Treatment
Decision-Making
Reproduction
Transplants
End-of-Life Care
Enteral Nutrition
Professional Associations
National Challenges         Sterilization
Bioterrorism                     Prison Challenges
 HIV Exceptionalism           Conflicts of Interest
Pharmaceutical Industry   Pregnancy
HIV Prevention   
Stigma
 Physician Reimbursement 
Ethics and Disease Challenges and Duties
 HIV Cure
 Ebola Virus Disease
 Executions






 
Ethics Main Page Main New and Noteworthy Home Page

Medical Advocates
Nevirapine (Viramune)
 
Journal Citations:
Therapeutic Strategies
 
Drug Monitoring                         Stopping NVP Therapies             
Tolerance Induction                   Adherence and Dosing 
Cryptococcal Prophylaxis           IDUs   
Lipodystrophy Prevention          HIV/TB Coinfection
HIV Pre-exposure Prophylaxis   HIV/Malaria Coinfection
Coronary Risk                             HIV/HCV Coinfection
CNS Benefits
 Undetectable Viral Load
 Switching Therapies
Simplification Therapy
 Salvage Therapy   
NVP Main Page  Journal Main Page Main New/Newsworthy  Home Page
Last Update:  April 13, 2017
  Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader
Drug Monitoring
 
 
Efavirenz and Nevirapine in HIV-1 Infection : Is There a Role for Clinical
Pharmacokinetic Monitoring?
 Dahri K, Ensom MH. 
Clin Pharmacokinet. 2007;46(2):109-32.
 Abstract

Efavirenz and nevirapine plasma levels in HIV-infected patients with hemophilia.
 Martorell M, Lopez RM, Ribera E
Enferm Infecc Microbiol Clin. 2005 Jun;23(6):349-5
 Abstract
Tolerance Induction
           
  Long-term safety and efficacy of nevirapine tolerance induction.
 Messaad D, Reynes J, Fabre J, et al.
Clin Exp Allergy. 2002 May;32(5):733-735.
 Abstract